ProPhase Labs : Condensed Investor Presentation

NASDAQ: PRPH

Corporate Presentation

January 2022

1

Forward Looking Statements

This presentation contains forward‐looking statements relating to our strategy and business objectives. All statements

other than statements of historical facts included in this presentation may be deemed to be forward‐looking statements including statements related to our plans to grow our new whole genome sequencing (WGS) business by leveraging our existing CLIA labs and retail relationships and to build a genomics database, our ability to offer competitive pricing and decreased turnaround times for our diagnostic and genome sequencing services, and our plans to acquire additional laboratories. You can identify forward-looking statements by words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of those terms, and similar expressions that convey uncertainty or future events or outcomes. These forward‐looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from those contemplated, projected, forecasted, estimated or budgeted, whether expressed or implied, by these forward‐looking statements including risks related to consumer demand for our diagnostic and genomic services, the competitive environment, challenges relating to entering into new business lines, the failure to obtain and maintain certain regulatory approvals, and our ability to continue to execute on our business plan. Additional risks and uncertainties relating to our business can be found under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2020 and our subsequent Quarterly Reports on Form 10-Q, as well as our other filings with the Securities and Exchange Commission. These forward-looking statements are based on current expectations, estimates, forecasts and projections and are not guarantees of future performance or development. The forward-looking statements contained in this presentation are made as of the date hereof, and we do not assume any obligation to update any forward-looking statements except as required by applicable law. Readers are cautioned not to place undue reliance on any forward-looking statements contained in this presentation.

2

ProPhase Timeline

History of Strong Execution

	Turns around and
	subsequently sells
	the Cold-EEZE cold
	remedy brand to
TURNAROUND	Mylan Pharma for
	$50 million.
Ted Karkus, CEO,	Develops new line
restructures and	of dietary
turns around the	supplements.
company. Stock	Continues lozenge
bottoms at $.65 per	manufacturing
share.	business.

SPECIAL DIVIDEND

Long term shareholders well rewarded as company pays out $1.80 per share in special dividends between 2018 - 2021.

COMMENCED COVID-19 TESTING

Expanded into Covid- 19 testing. Within a short period of time built a substantial business with a 25,000 sq. foot state- of-the art lab in Garden City, NY.

STRONG REVENUE GROWTH

Reported approximately $12 million Lab revenues on approximately 110,000 Covid-19 tests.

2012		2017

2018		Q4-2020		Q1 2021

ProPhase Diagnostics

• Acquired full service Clinical Laboratory Improvement Amendments (CLIA) accredited laboratory in New Jersey in October 2020. Built current capacity to process up to 10,000 tests per day.
• Subsequently built a second CLIA lab in Garden City, NY. 25,000 square feet. Current capacity to process 50,000 tests per day.
• Approved for a wide range of important diagnosis, screening and evaluation of diseases, including:

•

•

•

•

•

•

•

COVID-19 viral and antibody tests
COVID-19 antigen testing with results in 10-15 minutes
Respiratory Pathogen Panel (RPP) Molecular tests
Polymerase chain reaction (PCR) for Influenza A and B and RSV
Respiratory viruses
Pneumonia-causing bacteria
Other infectious diseases	4

ProPhase Diagnostics

• COVID-19is more contagious than the flu and has demonstrated its ability to mutate very quickly. Current scientific thinking is that COVID-19 may be with us for many years to come.
• Vaccination rates for COVID-19 are similar to flu. It is unclear whether there will ever be a high enough vaccination rate to negate COVID-19, in addition to the fact that vaccinations do not prevent all people from catching COVID-19 or spreading COVID-19. Vaccinations primarily reduce the symptoms of COVID-19.
• While COVID-19 cases may continue to go through cycles or waves, we expect a consistent baseline level of COVID- 19 testing for the foreseeable future. ProPhase Labs has developed a large and growing diverse customer base of independent pharmacies and concierge services. We have found that many prefer the convenience of these testing sites rather than making appointments at doctor's offices.

Source: https://www.nytimes.com/interactive/2021/world/covid-cases.html

5